Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer

Journal of Geriatric Oncology
Meghan S KaruturiSharon H Giordano

Abstract

Screening for potentially inappropriate medications (PIM) is recommended in older patients with cancer receiving chemotherapy, given the concern for adverse drug reactions, drug-drug interactions and non-adherence. Our objective was to determine the impact of PIM on outcomes in patients with breast and colorectal cancers receiving chemotherapy. We used data from the SEER-Medicare database, including patients >/= 66 years old with a diagnosis of Stage II/III breast and colorectal cancer made between 7/1/2007-12/31/2009. We used modified STOPP criteria to define baseline PIM as a dichotomous variable in the 4 months prior to diagnosis. STOPP criteria was used based on its performance as a robust measure of PIM. Outcomes measures included ER visits, hospitalizations, and death within 3 months from the last chemotherapy, and a composite of the three. We used Chi-square or Fisher's exact test to determine associations of PIM with covariates and outcomes, and Cox proportional hazards (PH) model for the time-to-event analysis. Final analysis included 1,595 patients with breast cancer and 1,528 patients with colorectal cancer. Frequency of baseline PIM by STOPP was 31.5% in the breast and 30.9% in the colorectal cohort. In the breast c...Continue Reading

Citations

May 28, 2020·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Li-Ju ChenBen Schöttker
Jul 28, 2019·Current Opinion in Supportive and Palliative Care·David N Blane, Marta Lewandowska
Jul 13, 2021·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Li-Ju ChenBen Schöttker
Oct 8, 2021·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lisanne N van Merendonk, Mirjam Crul

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.